Determinants of persistent post-COVID-19 symptoms: value of a novel COVID-19 symptom score

Background Being a newly emerging disease, little is known about its long-lasting post-COVID-19 consequences. The aim of this work is to assess the frequency, patterns, and determinants of persistent post-COVID-19 symptoms and to evaluate the value of a proposed novel COVID-19 symptom score. Patient...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Egyptian Journal of Bronchology 2021-12, Vol.15 (1), p.1-8, Article 10
Hauptverfasser: Galal, Islam, Hussein, Aliae A. R. Mohamed, Amin, Mariam T., Saad, Mahmoud M., Zayan, Hossam Eldeen E., Abdelsayed, Mustafa Z., Moustafa, Mohamed M., Ezzat, Abdel Rahman, Helmy, Radwa E. D., Abd_Elaal, Howida K., Al Massry, Nasrallah A., Soliman, Mohamed A., Ismail, Asmaa M., Kholief, Karima M. S., Fathy, Enas, Hashem, Maiada K.
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Background Being a newly emerging disease, little is known about its long-lasting post-COVID-19 consequences. The aim of this work is to assess the frequency, patterns, and determinants of persistent post-COVID-19 symptoms and to evaluate the value of a proposed novel COVID-19 symptom score. Patients with confirmed COVID-19 in a hospital-based registry were included in a cross-sectional study (the hospitals including Assiut University Hospital, Assiut Chest Hospital, Aswan University Hospital, and Aswan Specialized Hospital). The patient demographics, comorbid disorders, the mean duration since the onset of the symptoms, history of hospital or ICU admittance, and the treatment taken during the acute state, as well as symptom score before and after convalescence, were recorded. Results The most frequent constitutional and neurological symptoms were myalgia (60.0%), arthralgia (57.2%), restriction of daily activities (57.0%), and sleeping troubles (50.9%), followed by anorexia (42.6%), chest pain (32.6%), gastritis (32.3%), cough (29.3%), and dyspnea (29.1%). The mean total score of acute stage symptoms was 31.0 ± 16.3 while post-COVID 19 symptom score was 13.1 ± 12.6 ( P
ISSN:1687-8426
2314-8551
DOI:10.1186/s43168-020-00049-4